


CONTINUING EDUCATION

September 10-13, 2021 Denver, Colorado + Virtual



2021 Program Committee

2021 Program Committee

Co-Chairs

Larry Allen, MD, MHS, FHFSA Katherine E. Di Palo, PharmD, BCACP, BCGP, FHFSA Walter J. Koch, PhD Marianne R. Piano, PhD, RN

Program Committee

David Lanfear, MD, MS - Chair Rob DiDomenico, PharmD - Co-Chair Daniel Garry, MD, PhD - Co-Chair Cheryl Westlake, PhD, RN- Co-Chair Alpesh Amin, MD, MBA Mosi Bennett, MD, PhD Akshay Desai, MD, MPH Teri Diederich, NP Megan Fraser, DNP, ANP-C Alanna Morris, MD, MSc Ajith Nair, MD Amil Shah, MD, MPH Jeffrey Teuteberg, MD Sandip Zalawadlya, MD Amrut Ambardekar, MD Timothy Fendler, MD Ashley Hardin, MD Line Kemeyou, MD Melissa Owen, RN, PhD Jo Ellen Rodgers, PharmD Emily Tsai, MD



INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to

(ACFE), and the A Credentialing Cen

provide continuing education for the healthcare team.

Physicians

HFSA designates this live activity for a maximum of **54.00** *AMA PRA Category 1 Credits*[™]. Physicians should claim only credit commensurate with the extent of their participation in the activity.



Successful completion of this CME activity, which includes participation in the evaluation component and post-test with 75% passing score, enables the participant to earn up to **9.25** MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

Nurses

This educational activity is approved for Nursing Continuing Professional Development (NCPD) units by the Heart Failure Society of American, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum of **54.00** contact hours (which includes a number of hours of nursing pharmacology. See details below).

Pharmacology Hours for Nurses

For Nurses who require pharmacology hours for their certification or licensure renewal, this year the HFSA Annual meeting offers opportunities to accrue a maximum of **17.00** hours.

Saturday, September 11

2:00 PM - 3:00 PM Crash & Burn: Cardiogenic Shock in 2021 Credit Hour(s): 0.25 2:00 PM - 3:00 PM Sarcoidosis Credit Hour(s): 0.25

2:00 PM - 3:00 PM PM The Right Heart: No More the Forgotten Side *Joint Session with the Canadian HF Society (CHFS)* Credit Hour(s): 0.25

3:30 PM - 4:30 PM Digesting EMPEROR-Preserved: The Evolving Treatment of HFpEF and Use of SGLT2i Credit Hour(s): 1.00

3:30 PM - 4:30 PM Beyond PVR: Assessing and Managing the Dysfunctional Right Ventricle Credit Hour(s): 0.50

Sunday, September 12

8:00 AM - 9:15 AM Recent Advances and Update on Myocarditis *Joint Session with the Myocarditis Foundation* Credit Hour(s): 0.50

8:00 AM - 9:15 AM

Applying Genetics & Genomics in HF: Current Landscape & Future Directions Credit Hour(s): 0.50

8:00 AM - 9:15 AM Substance use in Tx and LVAD Candidates Credit Hour(s): 0.25

8:00 AM - 9:15 AM COVID and the HF Clinician Credit Hour(s): 0.50

8:00 AM - 9:15 AM Burned Out : Identifying and Managing Clinician Burnout and

Mental Wellness Joint Session with the American Association of Heart Failure Nurses (AAHFN) Credit Hour(s): 0.25

9:45 AM - 11:15 AM Cardio-oncology Credit Hour(s): 0.50

hfsa.org/hfsa2021 #HFSA2021

Pharmacology Hours for Nurses Continued

9:45 AM - 11:15 AM International Session - Universal Definition of HF Joint Session with the Heart Failure Association of the European Society of Cardiology (HFA-ESC) and the Japanese Heart Failure Society (JHFS) Credit Hour(s): 1.00

9:45 AM - 11:15 AM Optimizing LVAD Management Credit Hour(s): 0.50

9:45 AM - 11:15 AM Failing Organs in Patients with Advanced HF, Will a Cardiac Fix Fix the Rest? Credit Hour(s): 0.50

1:30 PM - 2:45 PM Innovation in Heart Transplant: The Future of the Field Credit Hour(s): 0.75

1:30 PM - 2:45 PM HFpEF Credit Hour(s): 0.50

1:30 PM - 2:45 PM Role of Diet, Nutrition, & Body Composition in Patients with HF Credit Hour(s): 0.25

3:15 PM - 4:30 PM Pulmonary Arterial Hypertension: Providing Comprehensive Care Based on Risk Credit Hour(s): 1.00

3:15 PM - 4:30 PM Virtual Health Credit Hour(s): 0.25

Monday, September 13

8:00 AM - 9:15 AM Reexamining the 2018 Change in Heart Transplant Allocation Decisions: Are We Better Off Now? *FDA Special Session* Credit Hour(s): 0.25 8:00 AM - 9:15 AM Defining Constructs of HF: Biomarkers to Symptoms Credit Hour(s): 0.25

8:00 AM - 9:15 AM Emerging Devices/Procedures for Heart Failure Credit Hour(s): 0.25

8:00 AM - 9:15 AM Care Transitions: Methods, Medications, Metrics, and More! Credit Hour(s): 0.50

9:30 AM - 10:30 AM Debate: Optimal Medical Therapy for HFrEF, Death of HVAD, and Oral Inotropy Credit Hour(s): 1.00

9:30 AM - 10:30 AM Current Concepts in Iron Deficiency and HF Credit Hour(s): 1.00

9:30 AM - 10:30 AM Peripartum Cardiomyopathy Credit Hour(s): 0.75

9:30 AM - 10:30 AM JNC New Investigator Award (Basic Science / Clinical) Credit Hour(s): 0.50

11:00 AM - 12:00 PM Late Breaking Clinical Trials II Credit Hour(s): 1.00

11:00 AM Late Breaking Clinical Trials II Credit Hour(s): 1.00

11:00 AM - 12:00 PM Clinical Conundrums (Multidisiplinary Case Discussion) Credit Hour(s): 1.00

11:00 AM - 12:00 PM Revasularization in HF Credit Hour(s): 0.50

hfsa.org/hfsa2021 #HFSA2021

Pharmacology Hours for Nurses Continued

12:15 PM - 1:15 PM

Unintended Side Effects: Polypharmacy, Adherence, & Financial Toxicity of Evolving GDMT for Heart Failure Credit Hour(s): 1.00

12:15 PM - 1:15 PM Cardiac Amyloidosis

Credit Hour(s): 0.50

Pharmacists



TThe Heart Failure Society of America is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). This event is accredited for up to **24.75** contact hours of knowledge-based CPE.

Pharmacist participants may earn up to **24.75** hours of knowledge-based CPE. To earn credit for the live session, participants must complete the online evaluation for each presentation attended and submit their NABP ID and DOB (MMDD).

Once evaluations are completed, CPE will be uploaded to CPE monitor within 60 days of the close of the activity. Pharmacists wishing to claim credit for attending the live session must fill out the session evaluation(s) no later than 11:59 PM EST on Monday, November 1, 2021. *Please Note: Live CPE sessions are recorded and will be available On-Demand. Learners attending the Live Session —in-person or live-streaming—will receive live credit designated with the L04-UAN codes, and the learners opting to watch the session(s) on-demand as a Home-Study session will receive Home-Study credit with the H04-UAN codes.

Saturday, September 11

2:00 PM - 3:00 PM

Sarcoidosis

ACPE UAN: JA4008267-0000-21-008-L04-P | ACPE UAN: JA4008267-0000-21-009-H04-P

(1.0 contact hours - knowledge-based)

3:30 PM - 4:30 PM

Digesting EMPEROR-Preserved: The Evolving Treatment of HFpEF and Use of SGLT2i

ACPE UAN: JA4008267-0000-21-010-L04-P | ACPE UAN: JA4008267-0000-21-011-H04-P *

(1.0 contact hours - knowledge-based)

3:30 PM - 4:30 PM

Beyond PVR: Assessing and Managing the Dysfunctional Right Ventricle ACPE UAN: JA4008267-0000-21-012-L04-P | ACPE UAN: JA4008267-0000-21-013-H04-P * (1.0 contact hours – knowledge-based)

Sunday, September 12

8:00 AM - 9:15 AM

Recent Advances and Update on Myocarditis Joint Session with the Myocarditis Foundation ACPE UAN: JA4008267-0000-21-014-L04-P | ACPE UAN: JA4008267-0000-21-015-H04-P *

(1.25 contact hours - knowledge-based)

8:00 AM - 9:15 AM

Substance use in Transplant and LVAD Candidates ACPE UAN: JA4008267-0000-21-016-L04-P | ACPE UAN: JA4008267-0000-21-017-H04-P *

(1.25 contact hours - knowledge-based)

8:00 AM - 9:15 AM

COVID and the HF Clinician ACPE UAN: JA4008267-0000-21-018-L04-P | ACPE UAN: JA4008267-0000-21-019-H04-P *

(1.25 contact hours - knowledge-based)

8:00 AM - 9:15 AM

Burned Out : Identifying and Managing Clinician Burnout and Mental Wellness *Joint Session with the American Association of Heart Failure Nurses (AAHFN)*

ACPE UAN: JA4008267-0000-21-020-L04-P | ACPE: UAN: JA4008267-0000-21-021-H04-P *

(1.25 contact hours - knowledge-based)

9:45 AM - 11:15 AM Late Breaking Clinical Trials I ACPE UAN: JA4008267-0000-21-022-L04-P | ACPE: UAN: JA4008267-0000-21-023-H04-P * (1.50 contact hours – knowledge-based)

9:45 AM - 11:15 AM Cardio-oncology ACPE UAN: JA4008267-0000-21-024-L04-P | ACPE UAN: JA4008267-0000-21-025-H04-P * (1.50 contact hours – knowledge-based)

CE Credit Information Pharmacy Hours Continued...

Pharmacy Hours Continued

9:45 AM - 11:15 AM International Session - Universal Definition of HF Joint Session with the Heart Failure Association of the European Society of Cardiology (HFA-ESC) and the Japanese Heart Failure Society (JHFS) ACPE UAN: JA4008267-0000-21-026-L04-P | ACPE UAN: JA4008267-0000-21-027-H04-P * (1.50 contact hours – knowledge-based)

9:45 AM - 11:15 AM Optimizing LVAD Management ACPE UAN: JA4008267-0000-21-028-L04-P | ACPE: UAN: JA4008267-0000-21-029-H04-P * (1.50 contact hours – knowledge-based)

9:45 AM - 11:15 AM Failing Organs in Patients with Advanced HF, Will a Cardiac Fix Fix the Rest? ACPE UAN: JA4008267-0000-21-030-L04-P | ACPE: UAN: JA4008267-0000-21-031-H04-P * (1.50 contact hours – knowledge-based)

1:30 PM - 2:45 PM Role of Diet, Nutrition, & Body Composition in Patients with HF ACPE UAN: JA4008267-0000-21-032-L04-P | ACPE: UAN: JA4008267-0000-21-033-H04-P * (1.25 contact hours – knowledge-based)

3:15 PM - 4:30 PM Pulmonary Arterial Hypertension: Providing Comprehensive Care Based on Risk ACPE UAN: JA4008267-0000-21-036-L04-P | ACPE: UAN: JA4008267-0000-21-037-H04-P * (1.25 contact hours – knowledge-based)

3:15 PM - 4:30 PM Virtual Health ACPE UAN: JA4008267-0000-21-038-L04-P | ACPE: UAN: JA4008267-0000-21-039-H04-P * (1.25 contact hours – knowledge-based)

Monday, September 13

8:00 AM - 9:15 AM Emerging Devices/Procedures for Heart Failure ACPE UAN: JA4008267-0000-21-040-L04-P | ACPE: UAN: JA4008267-0000-21-041-H04-P * (1.25 contact hours – knowledge-based) 8:00 AM - 9:15 AM

Care Transitions: Methods, Medications, Metrics, and More! ACPE UAN: JA4008267-0000-21-042-L04-P | ACPE: UAN: JA4008267-0000-21-043-H04-P *

(1.25 contact hours - knowledge-based)

9:30 AM - 10:30 AM

Debate: Optimal Medical Therapy for HFrEF, Death of HVAD, and Oral Inotropy ACPE UAN: JA4008267-0000-21-044-L04-P | ACPE: UAN: JA4008267-0000-21-045-H04-P * (1.00 contact hours – knowledge-based)

12:15 PM - 1:15 PM Unintended Side Effects: Polypharmacy, Adherence, & Financial Toxicity of Evolving GDMT for Heart Failure ACPE UAN: JA4008267-0000-21-048-L04-P | ACPE: UAN: JA4008267-0000-21-049-H04-P * (1.00 contact hours – knowledge-based)

12:15 PM - 1:15 PM Cardiac Amyloidosis ACPE UAN: JA4008267-0000-21-050-L04-P | ACPE: UAN: JA4008267-0000-21-051-H04-P * (1.00 contact hours – knowledge-based)

Criteria for Successful Completion

Successful completion of this continuing education activity includes participation in the evaluation post course evaluation. For those session designated for MOC credits, participants must also achieve a passing score of 75% on the evaluation's post-test.

See below for details on claiming credits while in the virtual meeting platform.

Claiming CE and MOC Credit

Claiming CE Credits

To claim CE credit, learners must complete a session-specific evaluation. Click the "Claim CE Credit" link on the bottom left-hand side of the screen in the session player on the Virtual Meeting Platform to access the session evaluation. Onsite attendees will find QR codes for CE / MOC credits on signage and the schedule at a glance available at the registration desk or at the CE kiosk near registration.

Attendees may also view a list of CE sessions and complete the corresponding post-session evaluation using this link: https://ceu.experientevent.com/HFS211

The deadline to claim CE credit is 11:59 PM EST on Friday, November 19, 2021.

Claiming MOC Credits

Learners seeking to claim contact hours in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program will be asked to complete a session pre-test prior to the start of the session. At the conclusion of the session, the participant must complete a session evaluation and pass the post-test assessment with a 75% score.

Learners must provide the HFSA with their 6-digit ABIM number along with their Date of Birth (MMDD). The HFSA will report all successfully obtained MOC contact hours directly to the ABIM.

To claim MOC credit, click the "Pre-Test" link on the bottom left-hand side of the screen in the session player on the Virtual Meeting Platform to access the session pre-test. Onsite attendees will find QR codes for CE / MOC credits on signage and the schedule at a glance available at the registration desk or at the CE kiosk near registration.

To see a list of MOC sessions with links to their corresponding pre-tests, use this link: https://hfsa.org/hfsa2021/moc

The deadline to claim MOC credit is 11:59 PM EST on Friday, November 19, 2021.

Pharmacy Credit: Additional Details

Learners seeking to claim continuing pharmacy education (CPE) credit hours must complete the online evaluation for each presentation attended and submit their NABP ID and DOB (MMDD). Once evaluations are completed, CPE will be uploaded to CPE monitor within 60 days of the close of the activity. Evaluations are available in the "Claim CE Credit" tab housed within the session player for a session offering CPE credits.

Pharmacists must fill out evaluation to claim credit by 11:59 PM EST on Monday, November 1, 2021.

Satellite Symposia Information



In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC),

to provide continuing education for the healthcare team.

Satellite symposia will each offer continuing education credit hours.

Please refer to the satellite handout materials for exact hours physician, nursing, and/or pharmacy credits where applicable.

Scientific Program Learning Objectives

Following this meeting, attendees will be able to:

- 1. Describe the epidemiology of HF and implement strategies for the prevention of HF.
- 2. Discuss the current scientific basis of HF from the perspectives of cardiovascular physiology, neurohormones, tissue factors, molecular biology, and genetics.
- 3. Identify the findings of basic science research and current clinical trials and describe their implications for current and future HF therapy.
- Implement optimal guideline-based therapeutic options for HF, including pharmacologic agents, non-pharmacologic options, such as diet and exercise; and implantable devices.
- 5. Manage comorbidities including hypertension, diabetes, depression, sleep apnea, and chemotherapy.
- 6. Demonstrate awareness of psychosocial, economic, regulatory, and ethical issues in the treatment of patients with HF.
- 7. Explain the patient, provider and system-related factors that contribute to racial and ethnic health disparities.
- 8. Implement strategies for effective management of the patient with HF, incorporating the family, encouraging self-care, and employing the team approach.
- 9. Outline strategies for transitioning patients from impatient to outpatient care and for reducing hospital readmissions.
- 10. Engage in performance measurement and other site-based research.

Specific learning objectives for each of the scientific sessions and satellite symposia are listed in the session description in the virtual meeting platform.

Competencies Addressed

The 2021 scientific program contains content that addresses the following ABMS core competencies:

- Patient care
- Medical knowledge
- Interpersonal and communications skills
- Professionalism
- Systems-based practice
- Sessions also address the following ABIM specified competency areas in advanced heart failure and transplant cardiology:
- Epidemiology and risk factors
- Pathophysiology of heart failure
- Hemodynamics and hemodynamic monitoring
- Heart failure and normal ejection fraction
- Heart failure with renal dysfunction / cardiorenal syndrome
- Diagnostic tests and procedures
- Acute decompensation of chronic heart failure
- Subset of patients with heart failure, including women, the elderly, and different racial or ethnic groups
- Heart failure comorbidities
- Heart failure and pregnancy
- Cardiomyopathies
- Pharmacotherapy
- Implantable devices
- Heart transplant
- Mechanical circulator support
- End-of-Life Issues

Presentation Information

Audience Response System

Instructions for Attendees:

For sessions utilizing audience response system for audience polling and Q&A, please follow these instructions:

Onsite Attendees

A QR code or URL will be provided in the session room. Learners will be able to participate using their mobile device or laptop.

Virtual Attendees

In the Virtual Meeting Platform, a link will be available on the session page.

Meeting Content

The HFSA Annual Scientific Meeting 2021 provides a forum for the open exchange and discussion of research results and scientific advancements in the field of heart failure; however, HFSA makes no representation or warranty as to the truth, originality, or accuracy of the information presented. Nor are the views expressed by the individual speakers necessarily the view of HFSA. HFSA supports the Joint Accreditation policy on evidence-based content and requires faculty to adhere to these standards when preparing a presentation.

Presenter / Planner Disclosure Information

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 12 months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

Speaker disclosure information is available in the virtual meeting platform Resources Hub. Speakers also have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the Joint Accreditation Updated Standards for Commercial Support.

Supporters

CE Satellite Symposium

The Heart Failure Society of America acknowledges the following for providing an unrestricted educational grant to support this year's Satellite Symposia.

American Regent Amyloidosis Research Consortium AstraZeneca Pharmaceuticals Bristol Myers Squibb Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Cytokinetics Incorporated Eidos Therapeutics Ionis Pharmaceuticals Merck & Co., Inc Pfizer Vifor Pharma

Interactive Workshops

The Heart Failure Society of America acknowledges the following for providing an unrestricted educational grant and/or in-kind donations to support this year's workshops.

Supported by unrestricted educational grants from:

Abbott ABIOMED

Supported by in-kind education donations from:

Abbott ABIOMED ActiCare Health Eko Medtronic Vyaire Medical

This is the CE Program only. For a complete listing of all meeting activities please refer to the Meeting Program.

| | | KEY | |
|---------------------|--------------|--|-----------------|
| CPE Pharmacy Cred | its SAT | Satellite Symposium | |
| MOC MOC Session | NPHARM | Nursing Pharmacology Credits | |
| Friday, Septemb | er 10, 2021 | | |
| 10:00 AM - 12:00 PM | | Easing the Burden of Hypertrophic Cardiomyopathy: Progress in Understanding & Addressing its Pathophysiology Supported by an educational grant by Bristol Myers Squibb | Colorado B |
| Saturday, Septer | nber 11, 202 | 21 | |
| 8:15 AM - 9:30 AM | SAT | Bridging the Iron Deficiency Chasm in Heart Failure: The Revolutionary Role of Intravenous Iron in Optimizing Outcomes Supported by an independent educational grant from American Regent | Colorado B |
| | SAT | Cardiac Amyloidosis: What Heart Failure Clinicians Need to Know Supported by education grants provided by the Amyloidosis Research Consortium, Eidos Therapeutics, Ionis Pharmaceuticals and Pfizer | Colorado C |
| 10:45 AM - 12:00 PM | | Plenary Session: Lessons for HF Care from the Pandemic: Imagining a Better New Normal | Aurora Ballroom |
| 2:00 PM - 3:00 PM | MOC | Crash & Burn: Cardiogenic Shock in 2021 | Colorado A |
| | | Sarcoidosis | Colorado B |
| | | Psychosocial Evaluation for Advanced HF Therapies: Are we evaluating patients fairly? | Colorado C |
| | | FDA Special Session – Focus on HFSA Research Network | Colorado D |
| | | The Right Heart: No More the Forgotten Side Joint Session with the Canadian HF Society (CHFS) | Red Rock 8/9 |
| 2:00 PM - 3:15 PM | WRKSHP | Interactive Workshop: CPET (CEUs) | Red Rock 6/7 |
| 3:30 PM - 4:30 PM | CPE | Digesting EMPEROR-Preserved: The Evolving Treatment of HFpEF and Use of SGLT2i | Colorado A |
| | | Referral for Advanced HF | Colorado B |
| | CPE | Beyond PVR: Assessing and Managing the Dysfunctional Right Ventricle | Colorado C |
| | | Deep Learning for HF Medicine: A Practical Primer | Colorado D |
| | | Women in HF | Red Rock 8/9 |

This is the CE Program only. For a complete listing of all meeting activities please refer to the Meeting Program.

| | | | KEY | |
|--------|-------------------|---------------------|--|--------------|
| CPE | Pharmacy Credi | its SAT | Satellite Symposium | |
| MOC | MOC Session | NPHARM | Nursing Pharmacology Credits | |
| Satu | rday, Septen | nber 11, 202 | 1 continued | |
| | | SAT | Demystifying Pharmacologic Therapy in HFrEF: Pivotal Opportunities to Improve Patient Outcomes Supported by an independent educational grant from Vifor Pharma | Colorado B |
| 7:30 P | 7:30 PM - 9:00 PM | SAT | Improving Pump Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Challenges and Opportunities Supported by an independent educational grant from Cytokinetics Incorporated | Colorado C |
| Sunc | day, Septemb | oer 12, 2021 | | |
| 6:45 A | M - 7: 45 AM | SAT | Expert Perspectives on SGLT2 Inhibitors: Reviewing Their Role in Type 2 Diabetes, Heart Failure and Chronic Kidney Disease Supported by an independent medical education grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company | Colorado A |
| | | MOC, NPHARM, CPE | Recent Advances and Update on Myocarditis Joint Session with the Myocarditis Foundation | Colorado A |
| | | MOC, NPHARM | Applying Genetics & Genomics in HF: Current Landscape & Future Directions | Colorado B |
| 8.00 V | M - 9:15 AM | NPHARM, CPE | Substance use in Transplant and LVAD Candidates | Colorado C |
| 0.00 A | IVI - 5.15 AIVI | NPHARM, CPE | COVID and the HF Clinician | Colorado D |
| | | NPHARM, CPE | Burned Out: Identifying and Managing Clinician Burnout and Mental Wellness <i>Joint Session with the American Association of Heart Failure Nurses</i> <i>(AAHFN)</i> | Red Rock 8/9 |
| 8:00 A | M - 9:30 AM | WRK | Hands-On Workshop: Acute Management of Cardiogenic Shock Seating limited; first come, first served | Red Rock 6/7 |
| | | CPE | Late Breaking Clinical Trials I | Colorado A |
| | | MOC, NPHARM, CPE | Cardio-oncology | Colorado B |
| 9:45 A | M - 11:15 AM | NPHARM, CPE | International Session - Universal Definition and Classification of HF Joint Session with HFA-ESC and JHFS | Colorado C |
| | | NPHARM, CPE | Optimizing LVAD Management | Colorado D |
| | | NPHARM, CPE | Failing Organs in Patients with Advanced HF, Will a Cardiac Fix Fix the Rest? | Red Rock 8/9 |

This is the CE Program only. For a complete listing of all meeting activities please refer to the Meeting Program.

 K E Y

 CPE
 Pharmacy Credits
 SAT
 Satellite Symposium

 MOC
 MOC Session
 NPHARM
 Nursing Pharmacology Credits

MOC,

NPHARM

NPHARM

9:30 AM - 10:30 AM

| Sunday, Septem | ber 12, 2021 | continued | |
|-------------------|--------------------------|---|--------------|
| | NPHARM | Innovation in Heart Transplant: The Future of the Field | Colorado A |
| 1:30 PM - 2:45 PM | MOC, NPHARM | HFpEF | Colorado B |
| | NPHARM, CPE | Role of Diet, Nutrition, & Body Composition in Patients with HF | Colorado C |
| | | Dismantling Historical Systems of Inequity to Improve Access to Advanced Heart Failure Therapies for Diverse Populations | Colorado D |
| 3:15 PM - 4:30 PM | NPHARM, CPE | Pulmonary Arterial Hypertension: Providing Comprehensive Care Based on Risk | Colorado A |
| | NPHARM, CPE | Virtual Health | Colorado B |
| | | Best of Journal of Cardiac Failure (JCF) and HF Journal Round Table | Colorado C |
| | | Innovative Strategies for Better LVAD Outcomes | Colorado D |
| 5:00 PM - 6:30 PM | SAT | SGLT2 Inhibition and Heart Failure: Translating the Evidence to Clinical Practice Supported by an educational grant from AstraZeneca Pharmaceuticals | Colorado B |
| | SAT | Emergence of Novel Therapies for the Management of HFrEF Supported by an educational grant from Merck & Co., Inc. | Colorado C |
| Monday, Septem | ber 13, 202 ⁻ | 1 | |
| 8:00 AM - 9:15 AM | NPHARM | Reexamining the 2018 Change in Heart Transplant Allocation Decisions: Are We Better Off Now? | Colorado A |
| | NPHARM | Defining Constructs of HF: Biomarkers to Symptoms | Colorado B |
| | CPE | Emerging Devices/Procedures for Heart Failure | Colorado C |
| | NPHARM, CPE | Care Transitions: Methods, Medications, Metrics, and More! | Red Rock 8/9 |
| | NPHARM, CPE | DEBATE: Optimal Medical Therapy for HFrEF, Death of HVAD, and Oral Inotropy | Colorado A |
| | | | |

Colorado C

Colorado D

Red Rock 8/9

Peripartum Cardiomyopathy

JNC New Investigators Award

Nursing New Investigator Award

This is the CE Program only. For a complete listing of all meeting activities please refer to the Meeting Program.

| | E i rogram omy | i i ei a eempi | to listing of all mosting dolivities please for to the mosting i regram. | |
|---------------------|----------------|------------------------|--|------------|
| | | | KEY | |
| CPE Pha | armacy Credits | SAT | Satellite Symposium | |
| MOC N | IOC Session | NPHARM | Nursing Pharmacology Credits | |
| Monday | , Septembe | er 13, 2021 | l continued | |
| 11:00 AM - 12:00 PM | | NPHARM | Late Breaking Clinical Trials II | Colorado A |
| | | NPHARM | Clinical Conundrums (Multidisciplinary Case Discussion) | Colorado B |
| | 12:00 PM | NPHARM | Revascularization in HF Joint Session with the Inter-American Society of Cardiology (IASC) | Colorado C |
| | | NPHARM, CPE | Unintended Side Effects: Polypharmacy, Adherence, & Financial Toxicity of Evolving GDMT for HF | Colorado D |
| 12:15 PM - 1:15 PM | | | Hyde Park JNC and Nursing Award Announcements | Colorado A |
| | 1:15 PM | MOC, NPHARM, CPE | Cardiac Amyloidosis | Colorado B |

2021 Exhibitors

The Heart Failure Society of America acknowledges the following for their participation as an exhibitor."

Booth Number Exhibitor Name

| 701. Abbott 510. ABIOMED 309. Alnylam Pharmaceuticals 914. Ambry Genetics, A Konica Minolta Company 208. American Association of Heart Failure Nurses (AAHFN) 709. BioCardia, Inc. 710. Boehringer Ingelheim Medical Information 611. Boehringer Ingelheim Pharmaceuticals, Inc. /Lilly USA LLC 411. Boston Scientific 715. Bristol Myers Squibb 815. CardioVere 308. CareDx, Inc. 415. CCS Trials 106. CMP Pharmaceuticals 808. Cormeum 101. CVRx 201. Cytokinetics 109. Daxor Corporation 215. Eidos Therapeutics 814. Endotronix 501. Impulse Dynamics 714. Invitae 102. Ionis Pharmaceuticals, Inc. 514. Itamar Medical 001. Medtronic 509. Merck & Co., Inc 822. Natera |
|--|
| |
| 509 Merck & Co., Inc |
| 822 Natera 400 Novartis Pharmaceuticals Corporation 918 Nuwellis, Inc. 723 OM1 |
| 002 Pfizer Medical Affairs - Rare Disease 904 Sensible Medical Innovations |
| 003 Stealth BioTherapeutics 811 SynCardia Systems, LLC |
| 910Ultromics |
| 211V-Wave, Inc. 615Vyaire Medical |
| 826ZOLL Medical |